Join
Live feed
·
PRReleasevia Quantisnow
Vera Therapeutics Inc. logo

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

ByQuantisnow·Wall Street's wire, on your screen.
VERA· Vera Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VERA (Vera Therapeutics Inc.) and more on Quantisnow.